Dr. Madduri on Challenges in Transplant-Eligible Patients With Myeloma
Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses challenges in the transplant-eligible myeloma population.
Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses challenges in the transplant-eligible myeloma population.
Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.
Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in…
In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
NOMINATE The Giants of Cancer Care ® program, presented by OncLive ®, recognizes and celebrates the individuals who have achieved landmark successes within the global…
Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.
Emiltatug ledadotin produced positive initial phase 1 data in breast, ovarian, and endometrial cancer, as well as adenoid cystic carcinoma type 1.
Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.